- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Terazosin - ...
MedChemExpress - Model Terazosin - 63590-64-7
Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].MCE products for research use only. We do not sell to patients.
Terazosin
MCE China:Terazosin
Brand:MedChemExpress (MCE)
Cat. No.HY-B0371
CAS:63590-64-7
Storage:Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping:Room temperature in continental US; may vary elsewhere.
Description:Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment.
In Vitro:Terazosin does not discriminate cloned α1-adrenoceptor subtypes transiently expressed in COS cells[1].
In Vivo:Terazosin can be used to promote stone discharge in treatment of ureteral stones. Terazosin is reportedly safe and effective in treatment of distal ureteral stones, especially stones >5 mm[3].
IC50 & Target:α adrenergic receptor
Hot selling product:Tirzepatide | Hoechst 33342 | Acetaminophen | Spermidine | ISRIB (trans-isomer) | Iptacopan (hydrochloride) | 6-Diazo-5-oxo-L-nor-Leucine | NAI-N3 | PNU-159682 | Abatacept
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References:
[1]. Michel MC, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8. [Content Brief]
[2]. Vincent J, et al. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8. [Content Brief]
[3]. Ju M, et al. Efficacy of combination terazosin and nifedipine therapy in postoperative treatment of distal ureteral stones after transurethral ureteroscopic lithotripsy. J Int Med Res. 2020 Apr;48(4):300060520904851. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
• It has a professional experimental center and strict quality control and verification system;
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
• The biological activity of the products has been verified by the experiments of customers in various countries;
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。